Published in J Neurol Sci on August 05, 2008
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. ACS Chem Neurosci (2013) 1.10
The Transcription Factor NURR1 Exerts Concentration-Dependent Effects on Target Genes Mediating Distinct Biological Processes. Front Neurosci (2011) 1.03
The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One (2012) 0.98
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential. Nat Rev Neurol (2013) 0.98
Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons. J Neurochem (2009) 0.93
Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. PLoS One (2010) 0.92
Developmental transcriptional networks are required to maintain neuronal subtype identity in the mature nervous system. PLoS Genet (2012) 0.92
Nuclear receptor unfulfilled regulates axonal guidance and cell identity of Drosophila mushroom body neurons. PLoS One (2009) 0.90
Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease. Toxicol Sci (2014) 0.89
Decreased level of Nurr1 in heterozygous young adult mice leads to exacerbated acute and long-term toxicity after repeated methamphetamine exposure. PLoS One (2010) 0.87
The lifelong maintenance of mesencephalic dopaminergic neurons by Nurr1 and engrailed. J Biomed Sci (2014) 0.87
Nuclear receptor 4A (NR4A) family - orphans no more. J Steroid Biochem Mol Biol (2015) 0.86
Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization. BMC Med Genomics (2016) 0.83
Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease. J Neural Transm (Vienna) (2010) 0.82
Nurr1 regulates Top IIβ and functions in axon genesis of mesencephalic dopaminergic neurons. Mol Neurodegener (2012) 0.82
The N-terminal region of Nurr1 (a.a 1-31) is essential for its efficient degradation by the ubiquitin proteasome pathway. PLoS One (2013) 0.80
Nurr1-Based Therapies for Parkinson's Disease. CNS Neurosci Ther (2016) 0.80
Dopamine Agonists Exert Nurr1-inducing Effect in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease. Chin Med J (Engl) (2015) 0.78
Effects of isoxazolo-pyridinone 7e, a potent activator of the Nurr1 signaling pathway, on experimental autoimmune encephalomyelitis in mice. PLoS One (2014) 0.78
Emerging roles of epigenetic mechanisms in Parkinson's disease. Funct Integr Genomics (2011) 0.78
Altered transcription factor trafficking in oxidatively-stressed neuronal cells. Biochim Biophys Acta (2012) 0.78
Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases. Cancer Lett (2015) 0.77
Identification of NURR1 (Exon 4) and FOXA1 (Exon 3) Haplotypes Associated with mRNA Expression Levels in Peripheral Blood Lymphocytes of Parkinson's Patients in Small Indian Population. Parkinsons Dis (2017) 0.75
Association of Nurr1 gene mutations with Parkinson's disease in the Han population living in the Hubei province of China. Neural Regen Res (2012) 0.75
Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed? J Neural Transm (Vienna) (2012) 0.75
Diagnostic criteria for Parkinson disease. Arch Neurol (1999) 11.65
Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry (2008) 7.20
Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol (2003) 6.86
Dopamine neuron agenesis in Nurr1-deficient mice. Science (1997) 5.40
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci U S A (1998) 2.76
Serum uric acid levels and the risk of Parkinson disease. Ann Neurol (2005) 2.47
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun (2006) 2.27
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Identification of a new brain-specific transcription factor, NURR1. Mol Endocrinol (1992) 2.11
Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain (2008) 2.10
Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord (2004) 1.79
Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol Cell Neurosci (1998) 1.75
Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol (2002) 1.32
The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol (2005) 1.30
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol (2006) 1.27
Low plasma uric acid level in Parkinson's disease. Mov Disord (2007) 1.22
Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem (1999) 1.21
Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology (1996) 1.15
NOT, a human immediate-early response gene closely related to the steroid/thyroid hormone receptor NAK1/TR3. Mol Endocrinol (1994) 1.12
Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol (2005) 1.10
Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol (1999) 1.09
Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology (2002) 1.08
Transcriptional regulation of mesencephalic dopaminergic neurons: the full circle of life and death. Mov Disord (2008) 1.07
Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov Disord (1999) 1.02
Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol Med (2003) 1.00
Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J Neural Transm (Vienna) (2001) 0.95
A Nurr1 point mutant, implicated in Parkinson's disease, uncouples ERK1/2-dependent regulation of tyrosine hydroxylase transcription. Neurobiol Dis (2007) 0.94
A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch Neurol (2003) 0.89
Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol (2005) 0.89
Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs. Ann N Y Acad Sci (2003) 0.86
Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. Neuroreport (1999) 0.82
(R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes. Ann Neurol (1998) 0.81
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Movement disorders in cerebrovascular disease. Lancet Neurol (2013) 2.81
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem (2005) 2.64
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol (2004) 2.46
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Camptocormia: pathogenesis, classification, and response to therapy. Neurology (2005) 2.26
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet (2006) 2.22
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord (2011) 2.16
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Genetic analysis of the F-box only protein 41 gene in Chinese Han patients with Parkinson's disease. Parkinsonism Relat Disord (2013) 1.97
Genetics of essential tremor. Brain (2007) 1.89
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord (2010) 1.76
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist (2008) 1.74
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res (2004) 1.65
Premutation alleles associated with Parkinson disease and essential tremor. JAMA (2004) 1.65
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun (2005) 1.64
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci (2004) 1.62
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61
Migraine headache in patients with Tourette syndrome. Arch Neurol (2003) 1.61
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat (2010) 1.57
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res (2010) 1.56
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol (2006) 1.55
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol (2005) 1.54
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol (2003) 1.53
Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. J Neurochem (2007) 1.52
Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord (2010) 1.52
Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem (2006) 1.48
Secondary tics and tourettism. Rev Bras Psiquiatr (2005) 1.47
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci (2011) 1.46
ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res (2008) 1.43
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis (2008) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol (2005) 1.39
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics (2010) 1.37
MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res (2009) 1.37
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry (2013) 1.36
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord (2003) 1.35
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin (2004) 1.33
Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J Neuropathol Exp Neurol (2004) 1.33
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord (2010) 1.31
Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals (2011) 1.30
Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol (2007) 1.30
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol (2006) 1.29
Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain (2006) 1.29
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol (2006) 1.27
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon (2013) 1.27
Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol (2002) 1.26
Runner's dystonia. J Neurol Sci (2006) 1.24
Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord (2004) 1.24
Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord (2006) 1.23
Novel polymorphisms of nuclear receptor SHP associated with functional and structural changes. J Biol Chem (2010) 1.23
Iron dysregulation in movement disorders. Neurobiol Dis (2012) 1.22
Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain (2009) 1.22
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A (2006) 1.20
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol (2013) 1.20
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna) (2013) 1.20
An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) (2013) 1.20